Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Cash & Equivalents (2023 - 2025)

Mangoceuticals (MGRX) has disclosed Cash & Equivalents for 3 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 2434.12% to $1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Dec 2025, up 2434.12% year-over-year, with the annual reading at $1.5 million for FY2025, 2434.12% up from the prior year.
  • Cash & Equivalents hit $1.5 million in Q4 2025 for Mangoceuticals, up from $101019.0 in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $1.5 million in Q4 2025 to a low of $58653.0 in Q4 2024.
  • Historically, Cash & Equivalents has averaged $503344.0 across 3 years, with a median of $101019.0 in 2025.
  • Biggest five-year swings in Cash & Equivalents: crashed 94.02% in 2024 and later skyrocketed 2434.12% in 2025.
  • Year by year, Cash & Equivalents stood at $1.2 million in 2023, then tumbled by 95.26% to $58653.0 in 2024, then surged by 2434.12% to $1.5 million in 2025.
  • Business Quant data shows Cash & Equivalents for MGRX at $1.5 million in Q4 2025, $101019.0 in Q2 2025, and $76496.0 in Q1 2025.